Part A of a safety and efficacy study successfully completed with nomacopan eye drops which were well tolerated with no serious adverse events. Improvement in mean composite clinical efficacy score of 35% by Day 14 and 55% by Day 56. All patients were on maximal dosage of cyclosporin, the standard

Positive initial clinical data reported in ongoing bullous pemphigoid (BP) and atopic keratoconjunctivitis (AKC) clinical trials Further clinical data from BP and AKC trials anticipated in 2019 Pivotal clinical trial for pediatric hematopoietic stem cell transplant-related thrombotic

In an experimental back of the eye, autoimmune uveitis (EAU) model to be reported in a poster presentation at ARVO 2019, nomacopan (Coversin) and its long acting variants administered intravitreally, reported: ○  Significant improvement in clinical scoring versus control ○  Co-localization of LTB4